Virginia Commonwealth University
Richmond, Virginia, 23298, United States
NCT Number: NCT05551156
The purpose of this research study is to test whether an animal-assisted intervention (AAI) is better than conversation with another person or treatment as usual for improving mood, anxiety, loneliness, quality of life, and indicators of health care services such as number of hospitalizations, length of hospital stay, and cost of services for children and adolescents.
Looking for future studies?
Notify Me8 year and older
All sexes
Interventional
Not applicable
Richmond, Virginia, 23298, United States
Rationale: Loneliness is linked to a number of health threats, is considered to be as harmful as smoking 15 cigarettes a day, and is potentially more dangerous than obesity. Loneliness was considered to be at epidemic proportions prior to the COVID-19 pandemic. The resulting need for social distancing has exacerbated loneliness and other mental health concerns. Loneliness is associated with significant morbidity and mortality risks among people with Mental Illness (MI). As many as 70% of community-dwelling adults with MI endorse experiencing loneliness, which increases exponentially with the number of co-morbid psychiatric diagnoses. A growing body of evidence indicates that companion animals offer a number of health and wellbeing benefits. Interacting with a trained therapy animal as part of an animal-assisted interaction (AAI) may provide social support for patients with mental illness, thus reducing the risk of loneliness. The use of AAIs for hospitalized patients with MI as a strategy for reducing loneliness has been understudied. Scientists and practitioners need clear answers to some key questions before specific recommendations can be made.
Hypothesis/Objectives: 1. Evaluate the feasibility of a therapy dog visitation intervention (AAI) over four consecutive days on an inpatient psychiatry unit, compared to a conversational control intervention (CC), and a treatment as usual control condition (TU) in psychiatric inpatients; 2. Assess the efficacy of an AAI over four consecutive days, compared to CC, and a treatment as usual control condition (TU) in psychiatric inpatients; 3. Obtain information required to estimate sample size for a large randomized controlled trial (RCT) of a therapy dog visitation program in the population of psychiatric inpatients, combined with already funded pilot data from a sample of older adults to calculate power, determine sample size, and pursue federal funding for a large scale, multi-site, clinical trial.
Study Design and Methods: The proposed study employs a three-group RCT design to examine study implementation feasibility and effects of AAI compared to CC and TU conditions. The investigators will randomize 60 psychiatry inpatients to one of three conditions (AAI, CC, or TU) for a four-day treatment period.
Preliminary Data: Demonstrated reductions in anxiety and fear in hospitalized psychiatric patients following brief AAI provide a foundation for this work.
Expected Results: The investigators anticipate that patients will demonstrate greater improvements in the primary outcome of loneliness, and in the secondary mental health and well-being outcomes of anxiety, depression, HRQOL and mood in the therapy dog visitation program compared to the CC and TU conditions from phase 1-4 and from pre to post intervention during phase 2. The investigators anticipate that at least 50% of patients approached will consent to participation in the study. The investigators anticipate greater than 75% adherence (session completion) and less than 25% attrition (failure to attend sessions) in the AAI and CC groups. The investigators anticipate similar rates of completion in phase 3 and phase 4 assessments in the three groups, with greater failure longer after study completion. The investigators anticipate that a high proportion (at least 75%) of patients will report satisfaction with the AAI (phase 3) and that the proportion will be higher than for the CC. The investigators will explore differences in willingness to consent, instrument completion (rates of missing data), and adherence and attrition across conditions.
Potential Impact on Human-Animal Bond Research: This proposal uniquely addresses loneliness, a critical mechanism that contributes to mortality and potential morbidity among people with serious mental illness. Completing the proposed research will allow us to collect necessary pilot data to support a larger, funded, fully powered RCT to test the effectiveness of therapy dog visitation as an adjunctive treatment for people with serious mental disorders . If findings support the superior efficacy of therapy dog visitation compared to other conditions, this information can be used not only to support its use as an inpatient intervention, but to provide a foundation for studying its utility in community-based mental health contexts, such as assertive community treatment, wellness action and recovery programs, and in supportive housing.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for children:
Inclusion criteria
for parents:
Exclusion criteria
Exclusion criteria
for children:
Exclusion criteria
for parents:
Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants with a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the participant will be able to pet the dog if they wish. The handler will talk with the participants about the dog, the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
Visits will occur on 3 consecutive days during your participant's inpatient hospital stay. A dog-handler team or a handler alone will visit participants without a dog for approximately 20 minutes at a convenient time for the participant. During this visit, the handler will talk with the participants about the weather, sports, or other light topics. Participants can also suggest light topics to talk about as well.
Time frame: Baseline to end of treatment (about 5 days), 1 month after treatment
Depressive symptomology will be measured with the 13-item Mood and Feelings Questionnaire (MFQ) which are rated on a 3 point scale. Higher scores indicate greater depression.
Time frame: Baseline to end of treatment (about 5 days), 1 month after treatment
Anxiety will be measured using the 6-item state scale of the State-Trait Anxiety Inventory for Children (STAI-C) which are rated on a 3 point scale. Higher scores indicate more anxiety.
Time frame: Baseline to end of treatment (about 5 days), 1 month after treatment
Mood will be measured using the Smiley Face Assessment Scale in which participants select which face fits their current mood. The scale depicts five emoticons from very sad to very happy.
Time frame: Baseline to end of treatment (about 5 days), 1 month after treatment
Child loneliness will be assessed using the 11-item version of the De Jong Gierveld Loneliness Scale for children which are answered on a 5 point scale. Higher scores indicate greater loneliness.
Virginia Commonwealth University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06260371
Bacterial Infections, Bacterial Infections and Mycoses
Créteil, France
View Trial DetailsNCT07418515
Hospitalized Children, Parent Stress
Karabük, Center, Turkey (Türkiye)
View Trial DetailsNCT03599674
Hospitalized Children
Seattle, Washington, United States
View Trial DetailsNCT03586180
Blood Disease, Cancer
Taipei, Taiwan
View Trial Details